Schild A F, Perez E, Gillaspie E, Seaver C, Livingstone J, Thibonnier A
University of Miami Miller School of Medicine, DeWitt Daughtry Family Department of Surgery, Miami, FL 33101, USA.
J Vasc Access. 2008 Oct-Dec;9(4):231-5.
Vascular access (VA) procedures are rapidly becoming the most prevalent surgery in the United States. It is estimated that there will be over 500,000 VA procedures done this year. Previously, surgeons in the US were attempting many more non-autogenous grafts than autogenous fistulae. In recent years, there has been a great push called 'Fistula First' to promote arteriovenous fistulae (AVF) as the first line of treatment vs. nonautogenous grafts. The goal of this investigation is to determine if too many fistulae are now being performed without attention to specific patient profiles.
A retrospective review of 1700 consecutive cases was performed by one surgeon at one institution between 1997 and 2005. Patients were categorized by demographics, co-morbidities, previous access procedures, access location, and type of graft. Patency was calculated. Kaplan-Meier, Cox regression and the Log Rank Test were used to analyze data. Access endpoints and complications were also documented.
The study reviewed 1700 procedures. The median age was 52 (60.2% male) with 58.7% fistulae and 41.3% grafts. Median patency time was 10 months, with no statistically significant difference between access types. There was no significant difference in length of patency when comparing upper arm (70.1%), lower arm (24.5%) and thigh (5.4%). Graft infection rate was 9.5% and fistula infection rate was 0.9% (p<0.001). The overall infection rate was 4.5%, and decreased patency significantly (4 vs. 11 months). Thrombosis occurred in 24.7% of grafts and 9.0% of fistulae. Thrombosed grafts had better salvage rates (8 vs. 4 months, p<0.001). The data showed diabetes, HTN and HIV have no overall impact on patency.
AVF and grafts are both useful in providing VA for patients requiring hemodialysis. Our data shows that grafts are equivalent in long-term patency. Therefore, it is apparent in those patients who are not candidates for an AV fistula; an AV graft for VA should be placed.
血管通路(VA)手术正迅速成为美国最常见的手术。据估计,今年将有超过50万例VA手术。此前,美国外科医生尝试的非自体移植物比自体动静脉内瘘更多。近年来,出现了一股名为“内瘘优先”的强大推动力,以促进将动静脉内瘘(AVF)作为相对于非自体移植物的一线治疗方法。本研究的目的是确定现在是否在未关注特定患者情况的前提下进行了过多的内瘘手术。
1997年至2005年期间,一名外科医生在一家机构对1700例连续病例进行了回顾性研究。患者按人口统计学特征、合并症、既往血管通路手术、血管通路位置和移植物类型进行分类。计算通畅率。采用Kaplan-Meier法、Cox回归和对数秩检验分析数据。还记录了血管通路终点和并发症情况。
该研究回顾了1700例手术。中位年龄为52岁(男性占60.2%),其中内瘘占58.7%,移植物占41.3%。中位通畅时间为10个月,不同血管通路类型之间无统计学显著差异。比较上臂(70.1%)、前臂(24.5%)和大腿(5.4%)时,通畅时长无显著差异。移植物感染率为9.5%,内瘘感染率为0.9%(p<0.001)。总体感染率为4.5%,并显著降低了通畅率(4个月对11个月)。24.7%的移植物和9.0%的内瘘发生了血栓形成。血栓形成的移植物有更好的挽救率(8个月对4个月,p<0.001)。数据显示糖尿病、高血压和艾滋病毒对通畅率无总体影响。
AVF和移植物在为需要血液透析的患者提供血管通路方面都很有用。我们的数据表明移植物在长期通畅方面是等效的。因此,对于那些不适合做AV内瘘的患者,显然应该植入AV移植物用于血管通路。